Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The impact of adjuvant therapy for patients with high-risk diffuse WHO grade II glioma.

Journal of neuro-oncology - 1 Dec 2017

Youland Ryan S, Kreofsky Cole R, Schomas David A, Brown Paul D, Buckner Jan C, Laack Nadia N

Abstract excerpt

Despite recent randomized, prospective evidence supporting use of RT and chemotherapy (CRT) for high-risk low-grade gliomas (LGG), many patients have historically received RT alone, chemotherapy alone or observation postoperatively. The purpose of this study is to evaluate outcomes for historical treatments in comparison to CRT for high-risk diffuse WHO grade II glioma patients. Records from 309 adults with WHO...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Chromosomes, Human, Pair 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Neoplasm Grading

Share to Survival Analysis

Share to Telomerase

Source

Identifiers

PMID: 28836106
DOI: 10.1007/s11060-017-2599-1

Genes

TERT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The impact of adjuvant therapy for patients with high-risk diffuse WHO grade II glioma.PMID 28836106Read ↗

Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation WHO grade II/III gliomas: A prospective randomized study.Semantic proximity Read ↗

Characteristics and outcomes of elderly patients with diffuse gliomas: a multi-institutional cohort study by Kansai Molecular Diagnosis Network for CNS Tumors.Semantic proximity Read ↗

Long-term outcomes in IDH-wildtype (IDH-wt) gliomas with historical WHO grade 2 and 3 histology.Semantic proximity Read ↗

Survival analysis of radiotherapy alone versus radiotherapy combined with temozolomide chemotherapy for low-grade gliomas: a meta-analysisSemantic proximity Read ↗

Age is associated with unfavorable neuropathological and radiological features and poor outcome in patients with WHO grade 2 and 3 gliomas.Semantic proximity Read ↗

TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.Semantic proximity Read ↗

The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wild type and -mutant lower grade gliomas.Semantic proximity Read ↗

Current management of low-grade gliomas.Semantic proximity Read ↗

Prognostic value of the extent of resection in supratentorial WHO grade II astrocytomas stratified for IDH1 mutation status: a single-center volumetric analysis.Semantic proximity Read ↗

The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma.Semantic proximity Read ↗

Molecular markers in low-grade gliomas: predictive or prognostic?Semantic proximity Read ↗

Impact of Resection on Survival of Isocitrate Dehydrogenase 1-Mutated World Health Organization Grade II Astrocytoma After Malignant Progression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.